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Introduction
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
was first identified in Wuhan, China, in December 2019 and then 
spread rapidly around the world. It became the causative agent of a 
respiratory syndrome named coronavirus disease 2019 (COVID-19) 
(1). SARS-CoV-2 mostly involves the respiratory system, although it 
affects other organs, including the gastrointestinal tract, liver, kidney, 
and skin (2). As reported, the severity of COVID-19 is directly 
correlated with the patient’s age and several comorbidities. However, 
no data are currently available regarding the clinical outcome in 
pediatric patients with chronic liver diseases (3). The mortality rate 
of COVID-19 has been reported around 3% in the general population, 
and most COVID-19 patients have been cured quickly (3).Children 
often have milder diseases than adults with extremely rare mortality(4). 
Despite the fact that COVID-19 diagnosis depends on virus genome 
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Coronavirus disease 2019 (COVID-19) is caused by the seventh 
coronavirus, known as the severe acute respiratory syndrome 
coronavirus 2(SARS-CoV-2). Children often have milder diseases than 
adults with very rare mortality. Gastrointestinal manifestations and a 
mild increase in liver enzymes have been reported in 8.8% to 53% of 
COVID-19 cases. However, liver failure is extremely rare and has not 
been reported so far in the literature. The prevalence of comorbidities 
is not clear in children with COVID-19. Here, we reported a fatal case 
of simultaneous pneumonia secondary to SARS-CoV-2and acute liver 
failure in a 14-year-old boy with liver cirrhosis. 
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RNA RT-PCR, a chest CT scan is useful in the 
early detection of pulmonary involvements before 
the onset of symptoms (5). Several studies reported 
gastrointestinal symptoms such as nausea, vomiting, 
diarrhea, and liver function abnormalities during 
the course of COVID-19 (6). This is a very rare 
presentation of liver involvement in COVID-19. 
The interaction between COVID-19 and liver 
function is still unclear, and more investigations 
should be carried out to clarify this interaction. 
Here, we presented a fatal case of superimposed 
COVID-19 pneumonia on chronic liver cirrhosis 
with a dominant feature of encephalopathy and 
acute liver failure.
In this report, we realized that a pediatric 
gastroenterologist and a pediatric neurologist 
need to consider liver involvement as a primary 
presentation of COVID-19. Moreover, a physician 
should consider acute liver failure in a patient with 
chronic liver disease as a complication of this viral 
infection.
Case presentation
A 14-year-old boy, G2P2L2A0, presented with 
an abdominal protrusion, lower extremities 
pitting edema, icter, and weight gain. He was 
under observation of pediatric nephrologists 
with an impression of nephrotic syndrome due 
to proteinuria for40 days. Due to abnormal liver 
function tests with prolonged prothrombin time 
and INR, he was transferred to our hospital. Three 
days before admitting to our hospital, he developed 
a dry cough, ascites, and an increase in yellowish 
discoloration of skin and sclera. Before admission, 
he had a weight gain of about 8 kg. He had no 
history of fever, nausea, vomiting, oligouria, 
myalgia, and dyspnea, although he was in contact 
with his family members with cough.
At the time of admission, he was alert with GCS=15, 
and his sclera and skin were icteric. The patient 
was ill and toxic looking. Physical examination of 
the patients revealed a body temperature of36.7°C, 
a respiratory rate of 18/min, a blood pressure of 
110/70 mmHg, and a heart rate of 84 beats/min. 
Fine rales were heard in the left lung. The spleen 
was palpable 6cm below the costal margin and, 
the liver was detected about 8cm below the costal 
margin with a firm consistency. The abdomen was 
protruded due to moderate ascites. Stigmata of 
chronic liver disease such as spider hemangioma, 
palmar erythema, and caput medusa were observed 
in the abdominal examination. The lower extremities 
had 4+ pitting edema. Laboratory investigations 
revealed abnormal coagulation profile, direct 
hyperbilirubinemia, liver enzyme elevation, mild 
anemia with thrombocytopenia, hypophosphatemia, 
hyponatremia, hypomagnesemia, and hypokalemia. 
Laboratory findings are summarized in Table1. 
Serologic markers for viral hepatitis A, B, and C 
viruses, HIV, and cytomegalovirus were negative. 
The autoimmune hepatitis profile, ceruloplasmin, 
and 24-hr urine copper results are summarized in 
Table2. There was no specific key point in his past 
medical or family history.
Chest radiography revealed diffuse haziness 
through the left lung field. A spiral chest CT scan 
without contrast showed bilateral multifocal sub-
pleural ground-glass opacity with mild pleural 
effusion highly suggestive for COVID-19 (Figure 
1). Abdominopelvic ultrasonography revealed 
hepatomegaly with coarse echogenicity and 
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The first complete blood count (CBC) showed 
anemia, lymphopenia, and thrombocytopenia. 
Table 3summarizesserial CBC. The nasopharyngeal 
swab sample RT-PCR confirmed the diagnosis of 
COVID-19 pneumonia. The serial nasopharyngeal 
sample test for COVID-19 was positive for three 
consecutive weeks. The patient was treated with 
non-invasive ventilation, hydroxychloroquine 
(200mg BID), and supportive drugs, including 
ursodeoxycholic acid 250mg TDS, vitamin K 
intravenous 10mg daily, vitamin E 200 mg oral 
daily, spironolactone 25mg BD orally, albumin, 
calcium gluconate, glycophose, intravenous 
cefotaxime, cryoprecipitate, fresh frozen plasma, 
and fresh packed-cell. The results of several 
abdominal paracenteses were transudative and 
clear. The patient had an absolute indication for 
emergency liver transplantation, and despite an 
initial improvement, his condition subsequently 
worsened, and he gradually developed 
encephalopathy with mood and mental status 
changes such as day time sleeping, lethargy, tremor, 
and respiratory distress. Unfortunately, the patient 
died after 18 days of hospitalization with features 
of refractory pulmonary hemorrhage.
Table 1. Primary Laboratory findings*




Marker Value on 
admission




Na(mEq/L) 133 131 TP (g/dL) 5.5 6.1 6
K (mEq/L) 3.5 3.1 Alb (g/dL) 2.1 3.3 3.1
Ca(mg/dL) 7.2 7.6 AST(IU/dL) 392 58 100
P (mg/dL) 2 2.1 ALT(IU/dL) 234 92 108
Mg(mg/dL) 1.5 1.3 TB (mg/dL) 8.7 40 41
BS(mg/dL) 68 57 DB (mg/dL) 3.5 19.9 21
BUN(mg/dL) 7 8.5 Alkp (IU/L) 119 253 266






*Abbreviations: ALT, alanine transaminase; AST, aspartate aminotransferase; TP, total protein; Alb, albumin; TB, total bilirubin; 
DB, direct bilirubin; Na, sodium; K, potassium; BS, blood sugar; BUN, blood urea nitrogen; Ca, calcium; Cr, creatinine; Mg, 
magnesium; P, phosphate; LDH, lactate dehydrogenase.
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Table 2. Advanced Specific Tests for Liver Disease *
Marker Value Marker Value Marker Value
ANA 1/20 Ceruloplasmin (mg/dL) 30 HAV- Ab (IgM) 0.4
AMA <1/10 24hr Urine copper (micg/dL) 25 HBS-Ag (ECL) 0.8
ASMA <1/10 IgG (g/L) 16 HBs-Ab (ECL) <5 
ALKM1 <1/10 HCV-Ab (ECL) 0.5 HIV -Ab (ECL) 0.6
*Abbreviation: ANA, anti-nuclear antibody; AMA, anti-mitochondrial antibody; ASMA, anti-smooth muscle antibody; Anti-
LKM1, anti-liver kidney microsome type 1 antibody; ECL, electrochemiluminescence; HAV Ab, hepatitis A virus antibody; 
HBs Ab, hepatitis B surface antibody; HBs Ag, hepatitis B surface antigen; HCV-Ab, hepatitis C virus antibody; and IgM, 
immunoglobulin M; IgG, immunoglobulin G; HIV, human immune deficient virus.
Table 3. Complete Blood Count and Coagulation Profile*
Marker Value 1 Value 2 Value 3 Value 4
WBC(*106/L) 6300 3000 3400 14300
Hb (g/dL) 10.5 6.3 8 7.2
MCV (fL) 112 115 110 113
Plt(*106/L) 78000 46000 53000 69000
PMN (%) 76% 67 74 91
Lymph (%) 19% 28 18 7
PT (S) 37 30.7 24 28
INR 5.6 4.2 2.9 3.2
PTT (S) 50 75 66 80
*Abbreviations: Hb, hemoglobin; WBC; white blood cell; INR, international normalized ration; MCV, mean cell volume; PT, 
prothrombin time; PTT, partial thromboplastin time; Plt, platelet; PMN, polymorphonuclear; Lymph, lymphocyte.
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Figure 1. The chest CT scan without contrast in a 14-year-old boy with chronic liver cirrhosis. There are bilateral multifocal sub-pleural ground-glass 
opacities with mild pleural effusion highly suggestive for COVID-19.
Discussion
Several studies documented a mild increase 
in serum aminotransferase (14-53%) in many 
COVID-19 patients (6). This condition is similar 
to the past SARS outbreak, with liver impairments 
in up to 60% of infected patients (7). Furthermore, 
the prevalence of chronic liver disease is about 
2-11% in COVID-19 patients. Previous studies 
showed that pre-existing liver disease increased 
COVID-19 mortality as well as other chronic 
diseases like hypertension, cardiovascular disease, 
and diabetes mellitus (6). Evaluations showed 
that co-infection with COVID-19 and hepatitis 
B virus resulted in adverse outcomes and higher 
mortality (8).Hepatic dysfunction in COVID-19 
can be the result of direct liver infection, as the 
virus is extracted from stool samples. Immune-
mediated inflammation and uncontrolled cytokine 
production, drug toxicity, and hypoxia are other 
probable mechanisms of liver injury in COVID-19 
patients (9).
SARS-CoV-2affects the target organ by binding 
to the angiotensin-converting enzyme 2 receptor, 
which has been suggested to be expressed in liver 
and bile duct cells (6). Thus, SARS-CoV-2 may 
directly damage liver cells and cause clinical and 
laboratory signs of liver failure. Some studies 
mentioned the increased serum level of lactate 
dehydrogenase (LDH), aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), gamma-
glutamyl transferase (GGT), bilirubin, and alkaline 
phosphatase (ALP) in COVID-19 patients, and a 
greater level of ALT was related to worse prognosis 
(8, 10).
Our case had idiopathic chronic liver cirrhosis 
and was a candidate for liver transplantation. In 
the outbreak of COVID-19, the patient’s clinical 
condition deteriorated, and he developed ascites, 
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icter, and increased liver enzymes. Gradually, a 
chest CT scan showed dyspnea and encephalopathy 
symptoms with pulmonary abnormalities in the 
patient. Finally, he expired despite receiving 
treatment.
In conclusion, based on the evidence previously 
presented, liver failure has not been reported in 
COVID-19 patients, and it is only a presentation 
of multisystem inflammatory syndrome in children 
(MISC). Thus, unexplained liver dysfunction 
should be considered as a probable sign of 
complicated COVID-19 or MISC. To understand 
this, a screening test needs to be performed as soon 
as possible. It can be helpful in the early diagnosis 
and treatment of COVID-19 patients and also in 
the prevention of further morbidity and mortality.
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